Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02813135
Title European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (ESMART)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Gustave Roussy, Cancer Campus, Grand Paris

Advanced Solid Tumor

hematologic cancer


Ribociclib + Temozolomide + Topotecan

Adavosertib + Carboplatin


Lirilumab + Nivolumab

Irinotecan + Olaparib

Age Groups: child
Covered Countries ITA | FRA | ESP | DEU

No variant requirements are available.